Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors

Wiener Klinische Wochenschrift

Volumn 115, Issue 13-14, 2003, Pages 475-481

  Watzke, Herbert H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Gene diagnosis; Genetic defects; Hemophilia; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR; COMPLEMENTARY DNA;

BLEEDING; BLOOD CLOTTING DISORDER; DISEASE PREDISPOSITION; DNA DETERMINATION; DNA SEQUENCE; GENE MUTATION; HEMOPHILIA; HUMAN; LUNG EMBOLISM; MEDICAL DECISION MAKING; REVIEW; THROMBOPHILIA; THROMBOSIS; VEIN THROMBOSIS;

EID: 0042319224     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03041031     Document Type: Review

References (64)

1. Noyes CM, Griffith MJ, Roberts HR, Lundblad RL (1983) Identification of the molecular defect in Factor IX Chapel Hill. Proc Natl Acad Sci USA 80: 4200-4202
2. Bertina RM, Koelernan BP, Koster T, Rosendaal FR, Dirven RJ, de R, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein. Nature 369: 64-67
3. Lillicrap D, Holden JJ, Giles AR, White BN (1988) Carrier detection strategy in haemophilia A: the benefits of combined DNA marker analysis and coagulation testing in sporadic haemophilic families. Br J Haematol 70: 321-326
4. Goodeve AC (1998) Advances in carrier detection in haemophilia. Haemophilia 4: 358-364
5. Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J (1993) Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 5: 236-241
6. Naylor JA, Green PM, Rizza CR, Gianelli F (1993) Analysis of factor VIII mRNA reveals defects in everyone of 28 hemophilia A patients. Hum Mol Genet 2: 11-17
7. Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J (1993) Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 5: 236-241
8. Ljung RC, Sjorin E (1999) Origin of mutation in sporadic cases of haemophilia A. Br J Haematol 106: 870-874
9. Chu K, Wu S-M, Stanley T, Stafford DW, High KA (1996) A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 98: 1619-1625
10. Oldenburg J, Quenzel E-M, Harbrecht U, et al (1997) Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 98: 240-244
11. Oldenburg J, Kriz K, Wuillemin WA, et al (2001) Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIX Thr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb Haemost 85: 454-457
12. Neuhaus T, Hertfelder H-J, Hess L, Oldenburg J, Walger P, Vetter H (2001) Seltene Ursache einer schweren Weichteileinblutung unter Therapie mit Phenprocoumon. Dtsch Med Wochenschr 126: 754-756
13. Briüt E, Bertina RM, Van Tilburg NH, Veltkamp JJ (1982) Haemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med 306: 788-790
14. Veltkamp JJ, Meilof J, Remmeits HG, van der Vlerk D, Loeliger EA (1970) Another genetie variant of haemophilia B: haemophilia B Leyden. Scand J Haematol 7: 82-90
15. Reitsma PH, Bertina RM, Ploos van Amstel JK, Riemens A, Briet E (1988) The putative factor IX gene promoter in hemophilia B Leyden. Blood 72: 1074-1076
16. Ghanem N, Costes B, Martin J, Vidaud M, Rothschild C, Foyer-Gazengel C, Goossens M (1993) Twenty-four novel hemophilia B mutations revealed by rapid scanning of the whole factor IX gene in a French population sample. Eur J Hum Genet 1: 144-155
17. Crossiey M, Winship PR, Austen DEG, Rizza CR, Browniee GG (1990) A less severe form of haemophilia B Leyden. Nucleic Aeids Res 18: 4633
18. Hirosawa S, Fahner JB, Salier JP, Wu CT, Lovrien EW, Kurachi K (1990) Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Lüy-den. Proc Natl Acad Sci USA 87: 4421-4425
19. Freedenberg DL, Black B (1991) Altered developmental control of the factor IX gene: a new T to A mutation at position +6 of the F-IX gene resulting in hemophilia B Leyden. Thromb Haemost 65: 964
20. Royle G, Van De Water NS, Berry E, Ockelford PA, Browett PJ (1991) Haemophilia B Leyden arising de novo by point mutation in the putative factor IX promoter region. Br J Haematol 77: 191-194
21. Reitsma PH, Mandalaki T, Kasper CY, Bertina RM, Briet E (1989) Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (Hemophilia B Leyden phenotype). Blood 73: 743-746
22. Koeberl DD, Bottema CDK, Buerstedde JM, Sommer SS (1989) Functionally important regions of the factor IX gene have a low rate of polymorphism and a high rate of mutation in the dinucleotide CpG. Am J Hum Genet 45: 448-457
23. Crossley PM, Winship PR, Black A, Rizza C, Brownlee GG (1989) Unusual case of haemophilia B. Lancet 1: 960
24. Crossley M, Ludwig M, Stowell KM, De Vos P, Olck K, Brownice GG (1992) Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 257: 377-379
25. Bertina RM (2001) Genetic approach to thrombophilia. Thromb Haemost 86: 92-113
26. Bertina RM (1998) The prothrombin 20210 G to A variation and thrombosis. Curr Op Hematol 5: 339-342
27. Redondo M, Watzke HH, Stucki B, Sulzer I, Biasiutti FD, Binder BR, Furlan M, Lammle B, Wuillemin WA (1999) Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 19: 1020-1025
28. van Hylckama Vlies A, van der Linden IK, Bertina RM, Rosendaal FR (2000) High levels of factor IX increase the risk of venous thrombosis. Blood 95: 3678-3682
29. Kamphuisen PW, Eikenboom JC, Rosendaal FR, Koster T, Blann AD, Vos HL, Bertina RM (2001) High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115: 156-159
30. Jimenez-Boj E, Schuttrumpf J, Forberg E, Watzke HH, Huber K (2000) The decanucleotide polymorphism in the factor VII promoter predicts factor VII plasma levels but not the risk of acute coronary syndromes. J Thromb Thrombolysis 10: 23-28
31. de Visser MC, Poort SR, Vos HL, Rosendaal FR, Bertina RM (2001) Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 85: 1011-1017
32. Watzke HH, Schüttrumpf J (1999) A polymorphic site within the promoter region of coagulation FX is associated with FX plasma levels and acute coronary syndromes. Thrombosis Haemostasis 91: 627 (A)
33. Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N (2002) Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol 71: 285-290
34. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E (1997) A factor V genetic component differing from factor V R506Q contributes to activated protein C resistance phenotype. Blood 90: 1552-1557
35. Rosendaal FR, Koster T, vandenbroucke JP, reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85: 1504-1508
36. Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc, Evans AE, Samama MM, Cambien F (1993) Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb 13: 886-891
37. Zito F, Di Castelnuovo A, Amore C, D'Orazio A, Donati MB, Iacoviello L (1995) Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients. Arterioscl Throm Vasc Biol 17: 3489-3494
38. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG (2002) Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 100: 3-10
39. Doggen CJ, Bertina RM, Cats VM, Rosendaal FR (2000) Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 110: 935-938
40. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88: 3698-3703
41. Ridker PM, Hennekens CH, Miletich JP (1999) G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 99: 999-1004
42. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, Ardissino D, Palareti G, Bernardi F (1997) The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 17: 2418-2422
43. Longstreth WT Jr, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, Raghunathan TE, Koepsell TD, Reitsma PH (1998) Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 29: 577-580
44. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL (1997) A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 90: 1747-1750
45. Watzke HH, Schuttrumpf J, Graf S, Huber K, Panzer S (1997) Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb Res 87: 521-526
46. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP (1995) Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332: 912-917
47. Emmerich J, Aiach M (1995) Mutation in the factory V gene and the risk of myocardial infarction. N Engl J Med 333: 880-881
48. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM (1996) Factor V (Arg 506→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 75: 701-702
49. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, Tracy RP (1998) Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study Thromb Haemost 79: 912-915
50. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ (1995) Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 15: 783-785
51. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH (1997) Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89: 2817-2821
52. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR (1998) Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 97: 1037-1041
53. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, Mazzucco A, Bernardi F, Corrocher R (2000) Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 343: 774-780
54. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S (1991) A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 11: 540-546
55. Green F, Johansen LG, Grootendorst D, Temple A, Cruickshank JK, Humphries SE, Jespersen J, Kluft C (1994) New alleles in F7 VNTR. Hum Mol Gen 3: 384
56. Marchetti G, Patracchini P, Gemmati D, DeRosa V, Pinotti M, Rodorigo G, Casonato A, Girolami A, Bernardi F (1992) Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7). Hum Genet 89: 497-502
57. Iacoviello L, Di CA, de KP, D'Orazio A, Amore C, Arboretti R, Kluft C, Benedetta DM (1998) Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Eng J Med 338: 79-85
58. Doggen CJ, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR (1998) A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 80: 281-285
59. Feng D, Tofler GH, Larson MG, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Johnstone MT, Muller JE, D'Agostino RB, Levy D, Lindpaintner K (2000) Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 20: 593-600
60. Simmonds RE, Hermida J, Rezende SM, Lane DA (2001) Haemostatic risk factors in arterial disease. Thromb Haemost 86: 374-385
61. Anwar R, Stewart AD, Miloszewski KJ, Losowsky MS, Markham AF (1995) Molecular basis of inherited factor XIII deficiency: identification of multiple mutations provides insights into protein function. Br J Haematol 91: 728-735
62. Kohler HP, Stickland MH, Ossei-Geming N, Carter A, Mikkola H, Grant PJ (1998) Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 79: 8-13
63. Wartiovaara U, Perola M, Mikkola H, Totterman K, Savolainen V, Penttila A, Grant PJ, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A (1999) Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 142: 295-300
64. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P (2000) The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 95: 586-591